European radiopharmaceutical firms Nuclidium and Actithera have raised substantial venture capital rounds to advance their radiopharmaceutical development platforms. Nuclidium, headquartered in Basel and Munich, secured approximately $99 million in a Series B financing to further develop its radiopharmaceutical technologies. Meanwhile, Actithera, focused on fibroblast activation protein-targeted radiotherapy for cancer, closed a $75.5 million Series A financing despite operating initially with a limited leadership team. These financings underscore increasing investor interest in radiopharmaceuticals, driven by their potential to deliver targeted tumor radiation with reduced biological risk compared to antibody-drug conjugates. The efforts of these startups aim to expand radiopharmaceutical options beyond the prostate cancer treatment niche dominated by established players.